14.39  0.15 (1.05%)		09-10 16:00
Open: 14.28 High: 14.53 Volume: 749,794		Pre. Close: 14.24 Low: 14 Market Cap: 1,385(M)

Short term
Mid term
Targets	6-month :	18.73	1-year :	20.2
Resists	First :	16.03	Second :	17.29
Pivot price	15.31
Supports	First :	14	Second :	11.64
MAs	MA(5) :	14.49	MA(20) :	15.45
	MA(100) :	15.97	MA(250) :	14.44
MACD	MACD :	-0.5	Signal :	-0.3
%K %D	K(14,3) :	13	D(3) :	16.1
RSI	RSI(14): 35.7
52-week	High :	19.09	Low :	9.5

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AVDL ] has closed above bottom band by 20.7%. Bollinger Bands are 40% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	14.56 - 14.66	14.66 - 14.75
Low:	13.76 - 13.89	13.89 - 14
Close:	14.2 - 14.39	14.39 - 14.57

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Tue, 27 Aug 2024
Avadel Pharmaceuticals plc (AVDL): One of Oppenheimer’s Top Stock Picks For the Next 12 Months - Yahoo Finance

Sat, 24 Aug 2024
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives $24.57 Consensus Price Target from Analysts - MarketBeat

Thu, 08 Aug 2024
Avadel: Q2 Earnings Snapshot - Thehour.com

Thu, 08 Aug 2024
Avadel: Q2 Earnings Snapshot - The Advocate

Thu, 08 Aug 2024
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results - StockTitan

Sun, 28 Jul 2024
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near Future - Simply Wall St

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	96 (M)
Held by Insiders	8.323e+007 (%)
Held by Institutions	4.7 (%)
Shares Short	12,030 (K)
Shares Short P.Month	0 (K)

EPS	-9.723e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-111.7 %
Operating Margin	-30.8 %
Return on Assets (ttm)	-34.5 %
Return on Equity (ttm)	-99.6 %
Qtrly Rev. Growth	2 %
Gross Profit (p.s.)	0
Sales Per Share	0.57
EBITDA (p.s.)	-1.4
Qtrly Earnings Growth	-1.1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-114 (M)

PE Ratio	-0.01
PEG Ratio	-2.2
Price to Book value	0
Price to Sales	25.1
Price to Cash Flow	0

Dividend	0
Forward Dividend	1.177e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.